Published in final edited form as:

J Med Chem. 2008 December 25; 51(24): 7689–7696. doi:10.1021/jm8003009.

Development and Preclinical Studies of Broad-spectrum Anti-HIV Agent (3'*R*,4'*R*)-3-Cyanomethyl-4-methyl-3',4'-di-*O*-(*S*)-camphanoyl-(+)-*cis*-khellactone (3-Cyanomethyl-4-methyl-DCK)

Lan Xie^{*,†}, Huan-Fang Guo[†], Hong Lu[‡], Xiao-Mei Zhuang[†], An-Ming Zhang^{†,⊥}, Gang Wu^{†,||}, Jin-Xiu Ruan[†], Ting Zhou[§], Donglei Yu[§], Keduo Qian[§], Kuo-Hsiung Lee^{*,§}, and Shibo Jiang^{*,†}

[†]Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China

[‡]Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA

[⊥]College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China

^{||} State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China

[§]Natural Products Research Laboratories, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA

Abstract

In prior investigation, we discovered that (3'*R*,4'*R*)-3-cyanomethyl-4-methyl-3',4'-di-*O*-(*S*)-camphanoyl-(+)-*cis*-khellactone (**4**, 3-cyanomethyl-4-methyl-DCK) showed promising anti-HIV activity. In these current studies, we developed and optimized successfully a practical ten-step synthesis for scale-up preparation to increase the overall yield of **4** from 7.8% to 32%. Furthermore, compound **4** exhibited broad-spectrum anti-HIV activity against wild-type and drug-resistant viral infection of CD4⁺ T cell lines as well as peripheral blood mononuclear cells by both laboratory-adapted and primary HIV-1 isolates with distinct subtypes and tropisms. Compound **4** was further subjected to *in vitro* and *in vivo* pharmacokinetic studies. These studies indicated that **4** has moderate cell permeability, moderate oral bioavailability and low systemic clearance. These results suggest that **4** should be developed as a promising anti-HIV agent for development as a clinical trial candidate.

As of February 2008, thirty-two anti-HIV drugs have been licensed by the US Food and Drug Administration (FDA) (<http://www.fda.gov/oashi/aids/virals.html>). These compounds include eleven HIV protease inhibitors, seventeen nucleoside and nonnucleoside reverse transcriptase (RT) inhibitors, one fusion inhibitor, one entry inhibitor (CCR5 co-receptor antagonist), one integrase inhibitor, and one multi-class combination product. Clinical combinations of these drugs, known as highly active antiretroviral therapy (HAART), have significantly reduced the morbidity and mortality of AIDS. However, increasing numbers of HIV/AIDS patients on HAART regimens fail to respond to current antiretroviral drugs due to the emergence of drug-resistant HIV mutants.¹ Therefore, it is essential to develop additional potent anti-HIV drugs with novel mechanisms of action or resistance profiles different from those of current anti-HIV therapeutics.

To whom correspondence should be addressed. Phone: 86-10-68181014. Fax: 86-10-6821-1656. E-mail: lanxieshi@yahoo.com; Phone: 919-962-0066. Fax: 919-966-3893. E-mail: khlee@unc.edu; Phone: 212-570-3058. Fax: 212-570-3099. E-mail: sjiang@nybloodcenter.org.

In our prior studies, 3',4'-di-*O*-(*S*)-camphanoyl-(+)-*cis*-khellactone (**1**, DCK, Figure 1) ² and its analogs were identified as a novel class of anti-HIV agents with potent activity in H9 lymphocytes. Systematic modification of **1** provided more than 150 khellactone derivatives, including mono-, di-, and tri-substituted **1**-analogs, and their SAR study results have been published. ^{3, 4, 5, 6} Notably, mechanistic studies have demonstrated that **1** and its analogs do target HIV-1 RT; however, they do not interfere with its RNA-polymerase activity, but instead inhibit its DNA-dependent DNA polymerase activity. Thus, **1**-analogs suppress the production of double-stranded viral DNA from a single-stranded DNA intermediate, ⁷ in stark contrast to current HIV-1 RT inhibitors that block the generation of single-stranded DNA from a RNA template. This unique mechanism of action provides an opportunity to discover a novel NNRTI that remains effective against HIV-1 RT multi-drug resistant strains. Thus, we were strongly prompted to develop additional potent **1**-analogs as potential clinical trial candidates.

Due to its high potency and easy synthesis, 4-methyl-DCK (**2**) was chosen as the first drug candidate for preclinical studies. However, the poor bioavailability of **2** has limited its further development. Subsequently, another promising candidate 3-hydroxymethyl-4-methyl-DCK (**3**, HMDCK) showed moderate bioavailability, but lacked activity in a drug resistant strain. ⁸ Guided by SAR and 3D-QSAR results, ⁹ our research efforts next focused on the development of drug candidates with better pharmacokinetic profiles and potent anti HIV-1 drug-resistant activity. A cyano group shows good metabolic stability under most conditions. Moreover, it is also a good H-bond acceptor and can favorably interact with Tyr or Ser amino-acid residues on the NNRTI binding site surface, which are critical determinants for several NNRTIs affinities. ¹⁰ In addition, reported evidence suggests that by introducing a cyano group, such as seen with the potent anti-HIV drug etravirine, the binding affinity of a quinazoline inhibitor to its target (containing Tyr30 and Tyr50) increased dramatically by 30,000-fold, due to hydrogen bond formation between the cyano nitrogen and two phenol hydroxyls of two tyrosines. ¹¹ Based on the aforementioned evidence, the 3-cyanomethyl moiety was selected to replace the 3-hydroxymethyl group of **3**. As we expected, (3'*R*,4'*R*)-3-cyanomethyl-4-methyl-DCK (**4**) discovered through this study not only exhibited promising potency against wild-type HIV-1 replication in H-9 lymphocytes (Table 4), ⁶ but also showed activity against several resistant strains. In this paper, we report the broad-spectrum anti-HIV potency of **4** against wild-type and drug resistant viral stains, its pharmacokinetic, and a practical synthetic protocol for scale-up synthesis of this promising compound.

Chemistry

As stated above, because **4** is a good potential drug candidate for preclinical studies, a practical synthesis for scale-up of **4** is merited and has been developed. The total yield of **4** was significantly increased from 7.8% in the original seven-step synthesis ⁶ to 32% in the new ten-step synthesis with optimized conditions, as shown in Scheme 1 and Table 1. The key intermediate 3,4-dimethylseselin (**11**) was originally prepared from 3,4-dimethyl-7-hydroxycoumarin (**6**) by a two-step reaction (see Scheme 1, steps a,b): a) nucleophilic substitution with 3-chloro-3-methyl-1-butyne, followed by b) Claisen rearrangement and cyclization in *N,N*-diethylaniline at reflux temperature (>200 °C). However, formation of a linear pyranocoumarin isomer was unavoidable, resulting in lower yields and difficult purification in scale-up synthesis. Thus, the following alternative synthetic route was developed to synthesize intermediate **11** exclusively and efficiently. Acetylation of the 7-hydroxyl of **6** with refluxing acetic anhydride provided 7-acetoxycoumarin **7** in 96% yield. By using AlCl₃ and slowly heating to 180 °C, **7** underwent Fries arrangement providing 8-acetyl-7-hydroxycoumarin (**8**), which was easily purified by crystallization from EtOH, in an 83% yield. Meanwhile, we separated the filtrate by column chromatography to obtain a small amount of 6-acetylated isomer. The structures of **8** and its 6-acetylated isomer were identified by spectroscopic analysis, and HPLC showed that the crystalline **8** was pure, with no 6-acetylated

isomer being detected. Condensation of **8** with acetone in the presence of pyrrolidine yielded the fused angular pyranocoumarin **9** in an 81% yield. Reduction of the 4'-carbonyl of **9** with NaBH₄ in MeOH yielded **10**. Without purification, subsequent dehydration of **10** with TsOH exclusively generated key intermediate 3,4-dimethylseselin **11**, which was readily purified by crystallization from EtOH. This current five-step preparation of **11** from **6** has a total yield of 59%, which is much higher than the 38% yield obtained in the original two-step synthesis, even though it is three steps longer. Additionally, this modified route to the key intermediate **11** has additional advantages for scale-up synthesis: it avoids production of the linear isomer, does not require chromatographic purification, and eliminates use of the costly reagent 3-chloro-3-methylbutyne-1 and the environmental contaminant *N,N*-diethylaniline.

Sharpless asymmetric dihydroxylation of **11** yielded (3'*R*,4'*R*)-3,4-dimethyl-(+)-*cis*-khellactone, which was dried *in vacuo* and used directly, without further purification, in the acylation step with (*S*)-camphanic chloride in pyridine and CH₂Cl₂. (3'*R*,4'*R*)-3,4-Dimethyl-DCK (**12**) was produced in a two-step yield of ca. 77%, with less than 5% of the (3'*S*,4'*S*)-isomer, as measured by HPLC. Compound **12** was treated with *N*-bromosuccinimide at a mole ratio of 1:1.2 in refluxing benzene for 4 h to produce exclusively 3-bromomethyl-4-methyl-DCK (**13**)^{4, 6} in 97% yield. Even though both 3- and 4-methyl groups were present, bromination occurred regioselectively only at the 3-methyl. In addition to ¹H NMR shifts, the position of bromination was verified using NOE (Nuclear Overhauser Effect) measurement, in which the signals of a methyl singlet (2.41 ppm, s) and 6-proton (6.80 ppm, d, *J* = 8.8 Hz) showed obviously increased response of ca. 14% and 12%, respectively, when the 5-proton (7.61 ppm, d, *J* = 8.8 Hz) was irradiated. This fact indicated that the 3-methyl has higher reactivity than the 4-methyl during free-radical type bromination.

Another major improvement was the cyanation of **13**. In our original synthesis, compound **13** was reacted with sodium cyanide in DMSO at 60 °C to give **4** in a 49% yield.⁶ However, DMSO is an environmental contaminant and not a suitable solvent for scale-up synthesis of a drug candidate, especially when used in the last step. Nitriles are generally prepared by reacting primary alkyl halides with inorganic metal cyanide salts; thus, a suitable solvent system in which both kinds of reagents are soluble is very crucial. We investigated the impact of various solvents and phase-transfer catalysts as shown in Table 2 to find a better solvent system. Accordingly, we tried first to use the polar aprotic solvent anhydrous DMF or acetonitrile rather than DMSO (entries 1 and 2, respectively). After stirring at room temperature for 24 h, both reactions failed because the inorganic sodium cyanide was barely soluble in these solvents. Adding a small amount of water to the DMF (DMF/water 60:1 v/v) greatly increased the solubility of sodium cyanide, resulting in a 75% yield of product (entry 3). However, the ¹H NMR spectrum of the product showed two different proton signals (δ 3.72 and 5.27 ppm) for the 3-CH₂ in a ratio of ca. 3.5:1, which indicated that the product was a pair of isomers. Each isomeric product could be obtained exclusively by using two-phase CHCl₃/H₂O in the presence of tetrabutylammonium iodide (Bu₄N⁺I⁻) when the reaction was carried out at room temperature (entry 4) or reflux (entry 5, 60–70 °C). The former conditions provided only one product (3-CH₂ signal at δ 3.72 ppm) and the latter conditions afforded the other product (3-CH₂ signal at δ 5.27 ppm) in ¹H NMR spectrum. Additional spectroscopic evidence (¹³C NMR, MS, and IR spectra) confirmed that the former product was the nitrile **4**, and the latter compound was the isonitrile isomer **4b**. Their spectroscopic differences are shown in Table 3. Products **4** and **4b** had HPLC retention times of 10.9 and 5.6 min, respectively.

Other phase-transfer catalysts, including benzyltriethylammonium chloride, methyltriethylammonium chloride, dibenzo-18-crown-6, and cetyltrimethylammonium chloride, were also investigated in the two-phase reaction system (data not shown), but Bu₄N⁺I⁻ gave better results. Addition of Bu₄N⁺I⁻ directly into DMF (entry 6) or acetonitrile (entry 7) improved the solubility of sodium cyanide and gave moderate yields of nitrile and

isonitrile, respectively, compared with failed entries 1 and 2. Furthermore, the effects of other polar aprotic or protic solvents with or without $\text{Bu}_4\text{N}^+\text{I}^-$ (entries 8–13) were investigated. Different solvents afforded either nitrile **4** or isonitrile **4b** exclusively. EtOH [containing water or anhydrous, with or without $\text{Bu}_4\text{N}^+\text{I}^-$ (entries 10–13)] showed high yields of nitrile **4**. Because EtOH is safe and inexpensive, it is usually a good solvent choice for scale-up synthesis. However, compound **13** had limited solubility in EtOH when the reaction scale was increased. Thus, a mixed solvent system of 95% EtOH/DMF (3:2 v/v) (entry 14) was developed. Alkyl bromide **13**, which is soluble in DMF, was added slowly to an EtOH solution of sodium cyanide over a 10–15 min period. After 2 h stirring at room temperature, this reaction produced only the expected cyanide **4** in a 74% yield. The $[\alpha]$ value of pure **4** is $+22.81^\circ$ in chloroform, in which 3'S,4'S stereoisomer of **4** was measured less than 0.5% by HPLC.

Results and Discussion

Broad-spectrum Anti-HIV Activity

In our previous studies, compound **4** exhibited similar potency to parent compounds **2** and **3**, but lower toxicity in HIV-1_{IIIB} infected H9 lymphocytes assay (Table 4).^{4,6} In the current study, we further tested compound **4** in other different assays, including laboratory-adapted, primary isolates and drug-resistant strains (Table 5, Table 6 and Table 7). It should be noted that, due to different protocols, the current assay is less sensitive. Further screening results indicate that compound **4** exhibited potent inhibitory activity against infection of CD4⁺ T cell lines and peripheral blood mononuclear cells (PBMCs) by laboratory-adapted and primary HIV-1 isolates. The inhibitory activity of **4** on infection of CD4⁺ T cells and, MT-2 and MT-4 cells by laboratory-adapted HIV-1 strains IIIB and Lai (X4-tropic virus), and Bal (R5-tropic virus) was determined as previously described.^{12,13} The *in vitro* cytotoxicity of **4** was assessed using a XTT assay.¹⁴ As shown in Table 5 and Table 7, compound **4** significantly inhibited infection by both X4- and R5-tropic viruses with EC_{50} values at sub-micromolar levels and selective index (SI) values ranging from 66 to 182. Subsequently, we sought to determine whether **4** is also effective against HIV-1 variants resistant to RTIs. As shown in Table 6, compound **4** had an EC_{50} of approximately 4 μM , for inhibiting infection by HIV-1 7324-1, which is a panel of fourteen prototypical infectious multidrug resistant HIV-1 reverse transcriptase (RT) clones, including those with each of the published nucleoside analog RT mutations in the combinations that occur most frequently in HIV-infected individuals.¹⁵ This value is about eight-fold higher than that against infection by wild-type HIV-1 IIIB. This result suggests that the multi-drug resistant HIV-1 variant is only moderately resistant to **4**, confirming that the newly synthesized **4** is an RTI with better resistance profiles than other RTIs

CD4⁺ T lymphocytes in PBMCs are the primary target cells for HIV-1 infection. Based on the HIV-1 envelope gene sequences, primary HIV-1 isolates can be classified into different genotypes, i.e. Group M subtypes A – H and Group O.^{16, 17, 18} A, C, D and G subtypes predominate in sub-Saharan Africa¹⁹, E subtype in Thailand,²⁰ and B subtype in the United States and Western Europe.²¹ HIV-1 isolates can be further classified into R5-, X4- and dual (R5X4)-tropic viruses, which use CXCR4, CCR4 or both coreceptors, respectively.^{17, 22, 23} We tested the inhibitory activity of **4** on infection by a series of primary HIV-1 isolates. As shown in Table 7, compound **4** significantly inhibited infection of PBMCs by all primary HIV-1 isolates tested, including subtypes A, B, C, D, G, and group O with R5- and X4R5 dual-tropisms. The EC_{50} values for inhibition of HIV-1 infection in PBMCs ranged from 0.8 to 10 μM . These results suggest that **4** has potent antiviral activity against a broad-spectrum of HIV-1 isolates.

Pharmacokinetic Studies

To be a useful anti-HIV drug candidate, a compound must be able to penetrate the cell membrane in order to interfere with replication steps inside the cell. In a colonic adenocarcinoma cell (Caco-2) assay, **4** had an apparent permeability coefficient (P_{app}) of 5.16×10^{-6} , indicating that it can readily penetrate the cell membrane.

In *in vivo* studies, compound **4** was administered via intravenous (i.v. 2 mg/kg) and oral (i.g. suspension, 20 mg/kg) routes to adult male Sprague-Dawley rats (180–200 g). Nine blood samples (0.4 mL) were collected sequentially over an 8-h period and immediately centrifuged. The separated plasma samples were stored at $-20\text{ }^{\circ}\text{C}$ for analysis. Pharmacokinetic parameters were calculated by non-compartmental analysis by using DAS Version 2.0. Initially, compounds **3** and **4** were administered as carboxymethylcellulose (CMC) suspensions, and although both compounds showed fairly low absorption *in vivo*, **4** was clearly better than **3** (Figure 2). To improve solubility and thus increase absorption *in vivo*, compound **4** was then administered in 10% poly(ethyleneglycol) (PEG) 400 to rats via intravenous and oral routes. Using this administration vehicle, **4** exhibited moderate oral bioavailability ($F = 17.8\%$) in the rat, as shown in Table 8 and Figure 3. Meanwhile, compound **4** also showed low systemic clearance (0.052 L/min/kg) and a moderate half time (167 min). Thus, current results indicate that the presence of the cyano moiety resulted in improved molecular pharmaceutical properties and provided lower lipophilicity, low systemic clearances, additional absorption, and longer half-life, subsequently enhancing oral bioavailability. Therefore, compound **4** should be further developed as a potential drug candidate.

Conclusions

Drug-resistance has become a critical problem in the development of new NNRTIs. However, further modification of **2** has led to the identification of **4** as a new promising lead for anti-HIV preclinical studies. It possesses not only potent antiviral activity against infection of CD4⁺ T cell lines and PBMCs by both laboratory-adapted and primary HIV-1 isolates with distinct subtypes and tropisms, but also moderate efficacy against multi-drug resistant HIV strains. In addition, a practical 10-step synthesis of **4** was successfully developed and optimized. In particular, the preparation of the key intermediate **11** and the cyanation in the final step were greatly improved. The modified synthesis gave a high overall yield of 32%, with minimized isomer formation, simplified purification, and elimination of high-cost reagents and toxic solvents, thus providing clear advantages for further scale-up synthesis. Pharmacokinetic studies also indicated that **4** has moderate oral bioavailability and cell permeability, and a reasonable half-life. All current results suggest that **4** has potential for development into an anti-HIV clinical trials candidate.

Experimental Section

General Information

Melting points were measured on a RY-1 melting apparatus without correction. ^1H NMR spectra were measured on a JNM-ECA-400 spectrometer using TMS as the internal standard. The solvent used was CDCl_3 unless otherwise indicated. Mass spectra were measured on a Perkin-Elmer Sciex API-3000 mass with Turbo Ion spray ionization. HPLC (Agilent 1100) experimental conditions were as follows: C18 column (15 cm $\times$ 0.4), 60% acetonitrile plus 25 mM HOAc/ H_2O as mobile phase, 1.5 mL/min flow rate, UV detection at $\lambda = 320\text{ nm}$. The diastereoisomeric excess percentages were measured by HPLC. Silica gel (GF₂₄₅ and 200–400 mesh) was purchased from Qingdao Haiyang Chemical Co., Ltd for TLC, PTLC, and column chromatography. A Flash+ system from Biotage, Inc. was used for medium-pressure

column chromatography. All other chemicals were obtained from Beijing Chemical Works or Aldrich, Inc.

3,4-Dimethyl-7-hydroxycoumarin (6)

A mixture of resorcinol (**5**, 44.0 g, 0.4 mol) and ethyl 2-methylacetoacetate (66 mL) in a 1:1.15 molar ratio was quickly dropped into H₂SO₄ (98%, 120 mL) with vigorous stirring at ice-bath temperature for 10–15 min. The mixture was stirred at room temperature for 2–3 h, poured into ice-water, and allowed to stand overnight. The precipitated white solid was filtered, washed with water until neutral, and dried *in vacuo* to produce 73.7 g of **6** (97% yield), colorless crystals from EtOH, mp 220 °C dec; ¹H NMR (CD₃OD) δ 2.11 (3H, s, CH₃-3), 2.38 (3H, s, CH₃-4), 6.65 (1H, d, *J* = 2.4 Hz, H-8), 6.77 (1H, dd, *J* = 2.4 & 8.8 Hz, H-6), 7.57 (1H, d, *J* = 8.8 Hz, H-5).

7-Acetoxy-3,4-dimethylcoumarin (7)

3,4-Dimethyl-7-hydroxycoumarin (**6**) (19.0 g, 100 mmol) in acetic anhydride (50 mL) was heated to reflux for 1.5 h. After cooling to 50 °C, the reaction mixture was slowly poured into ice-water (300 mL) with vigorous stirring. The solid was filtered, washed with water until neutral, and recrystallized from 95% EtOH (500 mL) to yield **7** as light yellow needles 22.3 g, 96% yield, mp 164–5 °C; ¹H NMR δ 2.21 (3H, s, 3-CH₃), 2.34 (3H, s, 4-CH₃), 2.39 (3H, s, 7-CH₃CO), 7.05 (1H, dd, *J* = 2.4 & 8.4 Hz, 6-H), 7.08 (1H, d, *J* = 2.4 Hz, 8-H), 7.60 (1H, d, *J* = 8.4 Hz, 5-H).

8-Acetyl-3,4-dimethyl-7-hydroxycoumarin (8)

7-Acetoxy-3,4-dimethylcoumarin (**7**) (23.2 g, 100 mmol) and anhydrous aluminum chloride (53.4 g, 400 mmol) were mixed and ground to a fine powder. The mixture was placed in a flask (500 mL) and heated from 130 °C to 180 °C (in an oil bath) within 2 h, and kept at 170–180 °C for another 2 h. After scraped ice (120 g) was added to the flask at room temperature, 5% aq HCl (300 mL) was slowly dropped into the flask with vigorous stirring. The mixture was then heated slowly to 110 °C and kept at the same temperature for 1 h to produce a suspension. The solid was filtered, washed until neutral, and then crystallized from EtOH (500 mL) to yield **8** (19.3g), 83% yield, yellow crystals, mp 175–176 °C; ¹H NMR δ 2.21 (3H, s, 3-CH₃), 2.39 (3H, s, 4-CH₃), 2.97 (3H, s, 8-CH₃CO), 6.91 (1H, d, *J* = 8.8 Hz, 6-H), 7.69 (1H, d, *J* = 8.8 Hz, 5-H), 13.46 (1H, s, 7-OH). A small amount of 6-acetyl-3,4-dimethyl-7-hydroxycoumarin, an isomer of **8**, was obtained via flash column chromatography from the crystallization filtrate, mp 213–214 °C; ¹H NMR δ 2.21 (3H, s, 3-CH₃), 2.42 (3H, s, 4-CH₃), 2.72 (3H, s, 6-CH₃CO), 6.85 (1H, s, 8-H), 7.97 (1H, s, 5-H), 12.56 (1H, s, 7-OH).

3,4-Dimethyl-3',4'-dihydroseselin-4'-one (9)

A mixture of **8** (23.2 g, 100 mmol), pyrrolidine (2 mL), acetone (20 mL, excess) and CH₂Cl₂ (100 mL) was stirred at room temperature for 48 h. The mixture was then poured into ice-water (50 mL), acidified with 5% aq HCl to pH 5–6, and extracted with CH₂Cl₂ three times. The organic phase was washed to neutral and dried over Na₂SO₄, and then the solvent was removed *in vacuo*. The residue was re-crystallized from EtOH to produce **9** as light yellow crystals: 25.8 g, 81% yield, mp 213–4 °C; ¹H NMR (DMSO) δ 1.43 (6H, s, 2'-CH₃×2), 2.07 (3H, s, 3-CH₃), 2.36 (3H, s, 4-CH₃), 2.83 (2H, s, 3'-CH₂CO), 6.95 (1H, d, *J* = 8.8 Hz, 6-H), 7.91 (1H, d, *J* = 8.8 Hz, 5-H).

3,4-Dimethyl-4'-hydroxy-3',4'-dihydroseselin (10)

NaBH₄ (11.4 g, 300 mmol) in water (50 mL) was dropped into a solution of **9** (27.2 g, 100 mmol) in MeOH (300 mL) at ice-bath temperature. Adding a few of drops of 1 M aq NaOH kept the reaction in a basic condition. The mixture was stirred at room temperature for 12 h

until the reaction was complete (TLC, petroleum/EtOAc 4:1). The pH was adjusted to 5–6 with aq 5% HCl, and the mixture extracted with EtOAc three times. The organic phase was washed with 5% NaHCO₃, water, and brine successively. After drying over anhydrous Na₂SO₄, the solvent was removed *in vacuo* to give crude **10** (25.5 g, 93% yield). The crude product could be used in the next reaction without further purification. It was also purified by a flash silica chromatography (eluant EtOAc/petroleum ether 0–30%) to give a light yellow solid, mp 166–167 °C; ¹H NMR δ 1.41 and 1.47 (each 3H, s, 2'-CH₃), 2.13 (2H, d, *J* = 5.2 Hz, 3'-CH₂), 2.19 (3H, s, 3-CH₃), 2.38 (3H, s, 4-CH₃), 3.23 (1H, s, 4'-OH), 5.26 (1H, m, 4'-H), 6.78 (1H, d, *J* = 9.2 Hz, 6-H), 7.45 (1H, d, *J* = 9.2 Hz, 5-H).

3,4-Dimethylseselin (**11**)

Compound **10** (27.4 g, 100 mmol) in anhydrous benzene (250 mL) in the presence of TsOH (2 g, catalytic amount) was heated to reflux for 15 min with TLC monitoring (petroleum ether/EtOAc 10:1). After cooling to room temperature, more EtOAc was added to the mixture, and the organic phase was washed successively with 10% aq NaOH, water and brine, and dried over anhydrous Na₂SO₄. After removing solvent *in vacuo*, the residue was purified by a flash column (silica, eluant: 0–10% EtOAc/petroleum ether) to give 25.0 g of **11**, 98% yield, colorless needle crystals from EtOH/H₂O mp 135–136 °C (lit. 121–122 °C); ¹H NMR δ 1.47 (6H, s, 2'-CH₃×2), 2.18 (3H, s, 3-CH₃), 2.35 (3H, s, 4-CH₃), 5.71 (1H, d, *J* = 9.6 Hz, 3'-H), 6.72 (1H, d, *J* = 8.8 Hz, 6-H), 6.91 (1H, d, *J* = 9.6 Hz, 4'-H), 7.35 (1H, d, *J* = 8.8 Hz, 5-H).

3,4-Dimethyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (**12**)

A mixture of K₃Fe(CN)₆ (20 g, 60 mmol), K₂CO₃ (10 g, 72.5 mmol), 2,5-diphenyl-4,6-bis(9-Odihydroquiny)l pyrimidine [(DHQ)₂-PYR] (531 mg, 0.6 mmol), and K₂OsO₂(OH)₄ (220 mg, 0.6 mmol) was solubilized in 260 mL of *t*-BuOH/H₂O (v/v, 1:1) at room temperature. Then, the solution was cooled to 0 °C, and methanesulfonamide (1.9 g, 20 mmol) added under stirring. When the solution turned from light yellow to orange, **11** (5.1 g, 20 mmol) was added. The mixture was stirred at 0 °C for 24 h. Na₂S₂O₅ (excess), water, and more CHCl₃ were added. After stirring for 0.5 h at room temperature, the mixture was extracted with CHCl₃ three times. The combined organic layer was dried over MgSO₄, then solvent was removed *in vacuo* to give 3,4-dimethyl-(+)-cis-khellactone, which was acylated directly, without further purification, with (S)-(-)-camphanic chloride (13.0 g, 60 mmol) in pyridine/CH₂Cl₂ (100 mL with 3:5 v/v) for 24 hours at room temperature monitored by TLC (cyclohexane/EtOAc 7:3). The mixture was diluted with EtOAc and washed successively with 10% aq HCl, water and brine. The organic phase was dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo*. The residue was separated by a flash column eluting with a 0–50% gradient of EtOAc/hexane to give 5.0 g of pure **12** (77% yield), as calculated from **11**, with 99.0 % stereoselectivity for (3'*R*,4'*R*)-isomer measured by HPLC.

3-Bromomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (**13**)

A mixture of **12** (19.5 g, 30 mmol) and N-bromosuccinimide (NBS, 6.4 g, 36 mmol) in 50 mL of anhydrous benzene was heated under reflux for 4 h until the reaction was completed as monitored by TLC. The mixture was cooled at 4 °C overnight, the solid filtered, and the solvent removed *in vacuo* to give a 19.7 g of **13** (97% yield), which was sufficiently pure to use in the next reaction without further purification.

3-Cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (**4**)

A solution of sodium cyanide (0.69 g, 14 mmol) in 40 mL of 95% EtOH was cooled in an ice-bath. Compound **13** (7.29 g, 10 mmol) in 15 mL of DMF was added slowly to the above solution over a 15–20 min period. After 2 h of stirring at room temperature, the mixture was poured into ice-water and extracted three times with EtOAc. The combined organic phase was washed

with brine, dried (MgSO₄), evaporated, and decolorized by passage through a short silica gel column (cyclohexane/acetone/CH₂Cl₂ 7:2:1) to afford the pure desired nitrile **4** (5.0 g, 74%); white solid, mp 164–166 °C, d.e% 99.0 (measured by HPLC), [α]_D +22.81° (*c* 1.01, CHCl₃); ¹H NMR δ 1.08–1.12 (m.s. 18H, 6×CH₃), 1.46 and 1.49 (each s, 3H, 2'-CH₃), 1.66, 1.91, 2.18, and 2.51 (each m, 2×CH₂), 2.52 (s, 3H, 4-CH₃), 3.72 (s, 2H, 3-CH₂), 5.40 (d, 1H, *J* = 4.8 Hz, 3'-H), 6.65 (d, 1H, *J* = 4.8 Hz, 4'-H), 6.89 (d, 1H, *J* = 8.8 Hz, 6-ArH), 7.62 (d, 1H, *J* = 8.8 Hz, 5-ArH); ¹³C NMR δ ppm 9.6 and 9.9 (2×CH₃), 15.7 (3-CH₂), 16.3, 16.4, 16.6, and 16.7 (4×CH₃), 21.2 (2×CH₃) and 26.1 (4-CH₃), 28.9, 29.0, 30.9, and 31.3 (4×CH₂), 54.6, 54.7, 54.9, and 55.1 (4×C), 61.5 and 72.1 (2×CH), 112.8 (CN), 90.7, 91.3, 106.3, 113.3, 116.3 (6×C), 114.9 and 127.2 (2×CH), 150.6, 152.2, 156.7, 159.2, 167.0, 167.4 (6×C), 177.4 and 178.6 (C=O); IR cm⁻¹ (KBr): 2972, 2935; MS (ESI) *m/z* (%): 676.5 ([M+1]⁺, 100), 693.5 (M +NH₄⁺, 48), 698.5 (M+Na⁺, 75). Anal. (C₃₇H₄₁O₁₁N) C 66.08, H 6.25, N 1.64, Calculated: C 65.77, H 6.12, N 2.07.

Isonitrile 4b

A mixture of **13** (73 mg, 0.1 mmol), Bu₄N⁺I⁻ (18.4 mg, 0.05 mmol), and sodium cyanide (11 mg, 0.22 mmol) in 10 mL of CH₃CN was stirred at room temperature for 12 h. The mixture was then poured into ice-water and extracted with EtOAc three times. The combined organic phase was washed with brine, and dried over MgSO₄. After removing the solvent *in vacuo*, the residue was separated by PTLC (eluant: cyclohexane/acetone 2:1) to give **4b** (36 mg, 53% yield); ¹H NMR δ 1.08–1.12 (m.s. 18H, 6×CH₃), 1.46 and 1.50 (each s, 3H, 2'-CH₃), 1.66, 1.91, 2.18, and 2.51 (each m, 2×CH₂), 2.52 (s, 3H, 4-CH₃), 5.27 (s, 2H, 3-CH₂), 5.38 (d, 1H, *J* = 4.8 Hz, 3'-H), 6.65 (d, 1H, *J* = 4.8 Hz, 4'-H), 6.88 (d, 1H, *J* = 8.8 Hz, 6-ArH), 7.63 (d, 1H, *J* = 8.8 Hz, 5-ArH); ¹³C NMR δ ppm 9.55 and 9.63 (2×CH₃), 15.26, 16.26, 16.36, 16.60, 16.66, and 21.14 (6×CH₃) and 26.13 (4-CH₃), 28.91, 28.96, 29.20, and 30.55 (4×CH₂), 54.20, 54.60, and 54.89, 55.04. (4×C), 59.74 (3-CH₂), 61.41, and 72.06 (2×CH), 90.72 (NC), 91.07, 91.30, 106.06, 113.44, 116.39 (5×C), 114.59 and 127.64 (2×CH), 152.35, 152.70, 156.62, 159.35, 166.89, 167.25 (6×C), 177.95, 178.01 and 178.51 (C=O); IR cm⁻¹ (KBr): 2341, 2360 (NC); MS (ESI) *m/z* (%): 676.5 ([M+1]⁺, 5), 649.5 (M-NC, 10).

Detection of HIV-1 replication as measured by p24 antigen production

MT-2 and MT-4 cells, laboratory-adapted HIV-1 strains and primary HIV-1 isolates were obtained from the NIH AIDS Research and Reference Reagent Program. The inhibitory activity of compounds on HIV-1 infection was determined as previously described.²⁴ In brief, 1 × 10⁴ MT-2 cells were infected with an HIV-1 strain (100 TCID₅₀) in 200 μ L RPMI 1640 medium containing 10% FBS in the presence or absence of a test compound at graded concentrations overnight. Then, the culture supernatants were removed and fresh media containing no test compounds were added. On the fourth day post-infection, 100 μ L of culture supernatants were collected from each well, mixed with equal volumes of 5% Triton X-100 and assayed for p24 antigen, which was quantitated by ELISA. Briefly, wells of polystyrene plates (Immulon 1B, Dynex Technology, Chantilly, VA) were coated with HIV immunoglobulin (HIVIG), which was prepared from plasma of HIV-seropositive donors with high neutralizing titers against HIV-1_{IIIB}, in 0.085 M carbonate-bicarbonate buffer (pH 9.6) at 4 °C overnight, followed by washes with washing buffer (0.01M PBS containing 0.05% Tween-20) and blocking with PBS containing 1% dry fat-free milk (Bio-Rad Inc., Hercules, CA). Virus lysates were added to the wells and incubated at 37 °C for 1 h. After extensive washes, anti-p24 mAb (183-12H-5C), biotin labeled anti-mouse IgG1 (Santa Cruz Biotech., Santa Cruz, CA), streptavidin-labeled horseradish peroxidase (Zymed, S. San Francisco, CA), and the substrate 3,3',5,5'-tetramethylbenzidine (Sigma Chemical Co., St. Louis, MO) were added sequentially. Reactions were terminated by addition of 1N H₂SO₄. Absorbance at 450 nm was recorded in an ELISA reader (Ultra 386, TECAN, Research Triangle Park, NC). Recombinant protein p24 purchased from US Biological (Swampscott, MA) was included for establishing standard dose

response curves. Each sample was tested in triplicate. The percentage of inhibition of p24 production was calculated as previously described.²⁵ The effective concentrations for 50% inhibition (EC₅₀) were calculated using a computer program, designated CalcuSyn²⁶, kindly provided by Dr. T. C. Chou (Sloan-Kettering Cancer Center, New York, New York).

Inhibitory activity of compound **4** against infection of PBMCs by a primary HIV-1 isolate was determined as previously described.²⁷ Briefly, PBMCs were isolated from the blood of healthy donors at the New York Blood Center by standard density gradient centrifugation using Histopaque-1077 (Sigma). The cells were cultured in 75 cm² plastic flasks at 37 °C for 2 h. The non-adherent cells were collected and resuspended at 5×10^6 cells in 10 mL of RPMI-1640 medium containing 10% fetal bovine serum (FBS), 5 µg/mL phytohemagglutinin (PHA) and 100 U/mL IL-2 (Sigma), followed by incubation at 37 °C for 3 days. The PHA-stimulated cells were infected with a primary HIV-1 isolate at a 0.01 multiplicity of infection (MOI) in the presence or absence of the test compound at graded concentrations. Culture media were changed on the second day and then every three days. The supernatants were collected seven days post-infection and tested for p24 antigen by ELISA as described above. The percent inhibition of p24 production and EC₅₀ values were calculated as described above.

Assessment of *in vitro* cytotoxicity

The *in vitro* cytotoxicity of compounds on MT-2 cells was measured by XTT assay.¹⁵ Briefly, 100 µL of the test compound at graded concentrations were added to equal volumes of cells (5×10^5 /mL) in wells of 96-well plates. After incubation at 37 °C for 4 days, 50 µL of XTT solution (1 mg/mL) containing 0.02 µM of phenazine methosulphate (PMS) was added. After 4 h, the absorbance at 450 nm was measured with an ELISA reader. The CC₅₀ (concentration for 50% cytotoxicity) values were calculated using a computer program, CalcuSyn.²⁸

Pharmacokinetic assessments

Chromatographic analyses were performed using a Gold ODS-C18 column (3 µm, 150 × 2.1 mm, Hypersil™ Thermo USA) kept at 20 °C, the mobile phase composed of acetonitrile–water–formic acid in the ratio of 65:35:0.1 (v/v/v) at a flow rate of 0.2 mL/min. Acetonitrile was HPLC grade and other chemical reagents and solvents were of analytical grade. A Thermo Finnigan TSQ tandem mass spectrometer equipped with ESI source (San Jose, CA, USA) and Surveyor LC pump were used for LC–MS/MS analysis. Data acquisition and data processing were performed by using Xcalibur software and LCQuan 2.0 data analysis program (Thermo Finnigan), respectively. Optimized MS parameters were as below: 4500 v spray voltage, 12.6 psi sheath gas pressure, 3.3 psi auxiliary valve flow, and 280 °C of capillary temperature. The selected reaction monitoring (SRM) mode was used and transitions selected for quantification were as follows: m/z 698.0 → m/z 292.8 for test compounds and m/z 285.1 → m/z 138.0 for internal standard (IS) synthesized by pharmaceutical laboratory. Optimized collision energy of 47 eV was used for test compounds and 21 eV for IS. Scan time was 0.5 s per transition. Solutions of test compounds and IS were infused into the mass spectrometer.

Preparation of samples

Using a simple protein precipitation method, a test compound was extracted from rat plasma. Plasma samples for standard curves were prepared by spiking 100 µL of rat plasma with 50 µL various concentrations of each test compound ranging from 10 to 10000 ng/mL and a constant volume (50 µL) of the internal standard (IS) (2 µg/mL in acetonitrile). The final concentrations of standards were set to 5, 10, 50, 100, 200, 1000, 2000, and 5000 ng/mL. To each tested plasma sample (100 µL), 50 µL of the same concentration of IS was added. The plasma was then mixed with 400 µL of acetonitrile. After vortexing and centrifugation at 10,000 g for 10 min, the supernatant was transferred to autosampler vials, and only 5 µL of the supernatant was injected into the LC-MS/MS system for analysis. The calibration curve y

$= ax + b$ was obtained by assigning the concentration of T and the peak area ratio of T to I.S. and to x and y , respectively. Subsequently, a $1/x$ weighted linear regression was performed. The amount of each test compound in the plasma samples was back-calculated using the standard curves.

***In vivo* animal test**

Three male Sprague–Dawley rats were used in each study. Each of these rats was dosed with a testing compound at 20 mg/kg for i.g. administration and 2 mg/kg for i.v. administration each in CMC. Blood samples were collected at 0, 5, 10, 30, 60, 120, 180, 240, 300 and 360 min (Figure 2) and were immediately centrifuged to separate the plasma fractions. When compound 4 was administered in 10% PEG400, the blood samples were collected at 0, 5, 15, 30, 60, 120, 180, 300, 480, and 720 min (Figure 3). The plasma samples obtained were stored at -20°C until analysis. Concentration-versus-time profiles were obtained for each analyte, and standard non-compartmental analysis was performed on the data using DAS Version 2.0 to recover the area under the curve (AUC) and other non-compartmental parameters. Bioavailability was estimated by dividing the dose-normalized AUC (0 - t) resulting from oral administration by the AUC (0 - t) resulting from intravenous administration (where t is the last time point with measurable drug concentrations in the study). Data for each pharmacokinetic parameter were averaged and reported as mean $\pm$ standard deviation. Calibration curves for testing compounds in plasma were linear in the concentration range of 5–5000 ng/mL, with correlation coefficients ≥ 0.990 for all curves.

Caco-2 cell experiment

Caco-2 monolayers exhibiting a transepithelial electrical resistance (TEER) value of more than $300\ \Omega\text{cm}^2$ were used within 21 days post-seeding. The culture medium was removed from both apical (AP) and basolateral (BL) sides and the monolayers were washed twice with warm phosphate buffered saline (PBS) with calcium and magnesium. The monolayers were pre-incubated at 37°C for 30 min in a CO_2 incubator with pre-warmed transport media. The transport medium consisted of Hanks Balanced Salt solution (HBSS), 10 mM HEPES buffer, 25 mM D-glucose, and the pH was adjusted to 7.4. Testing compounds at final concentrations of 10 mM in HBSS were added to the apical compartment. The basolateral compartment contained only HBSS. All transport studies were conducted in the AP to BL direction. At selected times, ranging from 10 to 60 min, 50 μL of samples were removed from the BL compartment for analysis and replaced with an equal volume of HBSS. Samples were analyzed using liquid chromatography mass spectrometry (LC/MS). The initial flux of the drug (J) was determined from the slope of the linear plot of the cumulative amount of drug transported versus time. Permeability was estimated by calculating the apparent permeability coefficient (P_{app})²⁹ according to: $P_{\text{app}} = J/\text{ASC}_0$, in which C_0 is the initial concentration in the donor compartment and AS is the surface area of the monolayer.

Acknowledgment

This investigation was supported by grants from Beijing Municipal Science & Technology Commission (D0204003041631) and from the National Natural Science Foundation of China (30271544) awarded to Lan Xie, and by NIH grant numbers AI 33066 and AI 46221 awarded to K. H. Lee and S. Jiang, respectively. The following reagents were obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: MT-2 and MT-4 cells, HIV-1 strains IIB, Lai, multidrug resistant HIV-1 reverse transcriptase (RT) clones, and the primary HIV-1 isolates.

References

1. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA. The prevalence of antiretroviral drug resistance in the United States. *AIDS* 2004;18:1393–1401. [PubMed: 15199315]

2. Huang L, Kashiwada Y, Cosentino LM, Fan S, Chen CH, McPhail AT, Fujioka T, Mihashi K, Lee KH. Anti-AIDS agents 15. Synthesis and anti-HIV activity of dihydroselelins and related analogs. *J. Med. Chem* 1994;37:3947–3955. [PubMed: 7525962]
3. Xie L, Takeuchi Y, Cosentino LM, Lee KH. Anti-AIDS agents 37. Synthesis and structure-activity relationships of (3'R,4'R)-(+)-*cis*-khellactone derivatives as novel potent anti-HIV agents. *J. Med. Chem* 1999;42:2662–2672. [PubMed: 10411486]
4. Xie L, Yu D, Wild C, Allaway G, Turpin J, Smith PC, Lee KH. Anti-AIDS agents 52. Synthesis and anti-HIV activity of hydroxymethyl (3'R,4'R)-3',4'-di-*O*-(*S*)-camphanoyl-(+)-*cis*-khellactone derivatives. *J. Med. Chem* 2004;47:756–760. [PubMed: 14736256]
5. Xie L, Takeuchi Y, Cosentino LM, McPhail AT, Lee KH. Anti-AIDS agents 42. Synthesis and anti-HIV activity of disubstituted (3'R,4'R)-3',4'-di-*O*-(*S*)-camphanoyl-(+)-*cis*-khellactone analogues. *J. Med. Chem* 2001;44:664–671. [PubMed: 11262077]
6. Xie L, Zhao CH, Zhuo T, Chen HF, Fan BT, Ma JZ, Li JY, Bao ZY, Yu D, Lee KH. Molecular modeling, design, synthesis, and biological evaluation of novel 3', 4'-Di-*O*-(*S*)-camphanoyl-(+)-*cis*-khellactone (DCK) analogues as potent anti-HIV agents. *Bioorg. Med. Chem* 2005;13:6435–6449. [PubMed: 16061386]
7. Huang L, Yuan X, Yu D, Lee KH, Chen CH. Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives. *Virology* 2005;332:623–628. [PubMed: 15680427]
8. Yu D, Chen CH, Brossi A, Lee KH. Anti-AIDS agents 60. Substituted 3'R,4'R-di-*O*-(–)-Camphanoyl-2',2'-dimethyldihydropyrano[2,3-*f*]chromone (DCP) as potent anti-HIV agents. *J. Med. Chem* 2004;40:72–4082. [PubMed: 15267246]
9. Chen HF, Fan BT, Zhao C-Y, Xie L, Zhao CH, Zhou T, Lee KH, Allaway G. Computational studies and drug design for HIV-1 reverse transcriptase inhibitors of 3',4'-di-*O*-(*S*)-camphanoyl-(+)-*cis*-khellactone (DCK) analogs. *J. Comput. Aided Mol. Des* 2005;19:243–258. [PubMed: 16163451]
10. de Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. *Med. Res. Rev* 1996;16:125–157. [PubMed: 8656777]
11. Kubinyi H. Hydrogen Bonding: The Last Mystery in Drug Design? *Pharmacokinetic Optimization in Drug Research* 2001 December;:513–523.
12. Jiang S, Lin K, Neurath AR. Enhancement of human immunodeficiency virus type-1 (HIV-1) infection by antisera to peptides from the envelope glycoproteins gp120/gp41. *J. Exp. Med* 1991;174:1557–1563. [PubMed: 1836013]
13. Neurath AR, Jiang S, Strick N, Lin K, Li Y-Y, Debnath AK. Bovine β -lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptors for HIV-1. *Nature Med* 1996;2:230–234. [PubMed: 8574970]
14. Debnath AK, Radigan L, Jiang S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. *J. Med. Chem* 1999;42:3203–3209. [PubMed: 10464007]
15. Dupnik KM, Gonzales MJ, Shafer RW. Most multidrug-resistant HIV-1 reverse transcriptase clones in plasma encode functional reverse transcriptase enzymes. *Antivir. Ther* 2001;6:42.
16. Korber, B.; Kuiken, C.; Foley, B.; Hahn, B.; McCutchan, F.; Mellors, J.; Sodroski, J. Human retroviruses and AIDS 1998. Los Alamos, NM: Los Alamos Laboratory; 1998. ppI-1-III-265
17. Berger EA, Doms RW, Fenyö EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA. A new classification for HIV-1. *Nature* 1998;391:240. [PubMed: 9440686]
18. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. *Science* 1993;261:1179–1181. [PubMed: 8356453]
19. Louwagie J, Janssens W, Mascola J, Heyndrickx L, Hegerich P, van der Groen G, McCutchan FE, Burke DS. Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. *J. Virol* 1995;69:263–271. [PubMed: 7983718]
20. Limpakarnjanarat K, Ungchusak K, Mastro TD, Young NL, Likhityingvara C, Sangwonloy O, Weniger BG, Pau CP, Dondero TJ. The epidemiological evolution of HIV-1 subtypes B and E among heterosexuals and injecting drug users in Thailand, 1992–1997. *AIDS* 1998;12:1108–1109. [PubMed: 9662211]

21. Myers G. Assimilating HIV sequences. *AIDS Res. Hum. Retroviruses* 1993;9:697–702. [PubMed: 8369174]
22. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. *Nature* 1996;381:661–666. [PubMed: 8649511]
23. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP. CD4-Dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. *Nature* 1996;384:184–187. [PubMed: 8906796]
24. Jiang S, Liu H, Liu S, Zhao Q, He Y, Debnath AK. N-Substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. *Antimicrob. Agents Chemother* 2004;48:4349–4359. [PubMed: 15504864]
25. Neurath AR, Strick N, Jiang S, Li YY, Debnath AK. Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of “dead-end” gp41 six-helix bundles. *BMC Infect. Dis* 2002;2:6. [PubMed: 11983022]
26. Chou, TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou, TC.; Rideout, DC., editors. *Synergism and Antagonism in Chemotherapy*. San Diego: Academic Press; 1991. p. 61-102.
27. Lu H, Zhao Q, Wallace G, Liu S, He Y, Shattock R, Neurath AR, Jiang S. Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. *AIDS Res. Hum. Retroviruses* 2006;22:411–418. [PubMed: 16706617]
28. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv. Enzyme Regul* 1984;22:27–55. [PubMed: 6382953]
29. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. *Biochem. Biophys. Res. Commun* 1991;175:880–885. [PubMed: 1673839]

- 1** $R_1 = R_2 = H$ (**DCK**)
- 2** $R_1 = H, R_2 = CH_3$
- 3** $R_1 = CH_2OH, R_2 = CH_3$ (**HMDCK**)
- 4** $R_1 = CH_2CN, R_2 = CH_3$
- 4b** $R_1 = CH_2NC, R_2 = CH_3$

Figure 1.
Structures of DCK analogs

Figure 2. Mean plasma concentration-versus-time curves of **3** and **4** with CMC after i.v. administration at 2 mg/kg (above) and i.g. administration at 20 mg/kg (bottom) to SD rats (n = 3) respectively.

Figure 3. Mean plasma concentration-versus-time curves of **4** in PEG400 after i.v. administration at 2 mg/kg (left) and i.g. administration at 20 mg/kg (right) to SD rats ($n = 3$), respectively.

Scheme 1. Synthesis of compound 4

(i) ethyl 2-methylacetoacetate/H₂SO₄; (a) 3-chloro-3-methyl-1-butyne/DMF/K₂CO₃/KI; (b) reflux in N,N-diethylaniline; (ii) Ac₂O; (iii) AlCl₃, high temperature; (iv) acetone/pyrrolidine; (v) NaBH₄/MeOH; (vi) TsOH/benzene, reflux; (vii) K₃Fe(CN)₆, K₂CO₃, (DHQ)₂-PYR, K₂Os₂(OH)₄, *t*-BuOH/H₂O (v/v=1:1), 0 °C; (viii) (*S*)-camphanic chloride, CH₂Cl₂/Py; (ix) NBS/benzene, reflux; (x) NaCN, see Table 2 for reaction conditions and products.

Table 1
Yields in original and new synthetic routes for target compound **4**

Steps	Improved yield (%)	Original yield (%) ^{3,6}
5→6	97	87
6→11	60 (5 steps)	38 (2 steps)
11→12	77	64
12→13	97	75
13→3	74	49
Total	32	7.8

Table 2
Solvent impact on preparing DCK nitrile (**4**) and isonitrile (**4b**) analogs

Entry	Solvent	Catalyst	Temp(°C)	Time (h)	Product(s)	Yield %
1	DMF	—	r.t.	24	—	
2	CH ₃ CN	—	r.t.	24	—	
3	DMF+H ₂ O	—	r.t.	6	nitrile/isonitrile 3.5/1	75
4	CHCl ₃ /H ₂ O	Bu ₄ N ⁺ I ⁻	r.t.	6	Nitrile	60
5	CHCl ₃ /H ₂ O	Bu ₄ N ⁺ I ⁻	60°C	6	Isonitrile	60
6	DMF	Bu ₄ N ⁺ I ⁻	r.t.	12	Nitrile	56
7	CH ₃ CN	Bu ₄ N ⁺ I ⁻	r.t.	12	Isonitrile	53
8	Acetone	Bu ₄ N ⁺ I ⁻	r.t.	12	Isonitrile	38
9	THF	Bu ₄ N ⁺ I ⁻	r.t.	24	Isonitrile	28
10	EtOH+H ₂ O	Bu ₄ N ⁺ I ⁻	r.t.	12	Nitrile	62
11	EtOH (anhydrous)	Bu ₄ N ⁺ I ⁻	r.t.	12	Nitrile	65
12	95% EtOH	—	r.t.	12	Nitrile	60
13	EtOH (anhydrous)	—	r.t.	12	Nitrile	62
14	95% EtOH+DMF (v/v 3:2)	—	r.t.	1	Nitrile	74

Table 3
Spectroscopic data differences between nitrile (**4**) and isonitrile (**4b**)

Spectra	Nitrile (4)		Isonitrile (4b)	
^1H NMR (δ ppm)	3.72	3- <u>CH_2</u> CN	5.27	3- <u>CH_2</u> NC
^{13}C NMR (δ ppm)	15.7	3- <u>CH_2</u> CN	59.5	3- <u>CH_2</u> NC
IR cm^{-1}	2972	2935	2341	2360 (NC)
MS (ESI) m/z (%)	676.5	($[\text{M}+1]^+$, 100)	676.5 ($[\text{M}+1]^+$, 5),	649.(M-NC,10)
HPLC ^a (R_t)	10.9 min		5.6 min	

^aHPLC: column: C18 Axxion, 15 cm $\times$ 0.4, mobile phase: 60% acetonitrile plus 25 mM HOAc/H₂O, 1.5 mL/min, λ = 320 nm.

Table 4

Anti-HIV activity comparison of DCK analog candidates **2**, **3**, and **4** in H9 lymphocytes in previous publications. ^{*4,6}

DCK analog	IC ₅₀ (μM)	EC ₅₀ (μM)	TI
2	23.6	0.0015 ⁴	15,733
3	24.9	0.004 ⁴	6,225
4	>37.0	0.0024 ⁶	15,417

* Data presented are averages of at least two separate experiments performed by Panacos Pharmaceuticals Inc.

IC₅₀ Concentration that inhibits uninfected H9 cell growth by 50%. EC₅₀ Concentration that inhibits viral replication by 50%. TI= IC₅₀ / EC₅₀. Assay method see reference. ^{4,6}

Table 5
Antiviral data of **4** against infection by laboratory-adapted HIV-1 strains in CD4+ T cell

Virus	Tropism	Cell line	CC ₅₀ (μM) ^a	EC ₅₀ (μM) ^b	SI
HIV-1 IIB	X4	MT-2	40.83 ± 3.59 ^c	0.47 ± 0.09	86.14
HIV-1 Lai	X4	MT-4	>100	1.51 ± 0.11	>66

^a XTT assay was used to determine the 50% cytotoxic concentration (CC₅₀) of **4**.

^b p24 ELISA was used to determine 50% effective concentration (EC₅₀) of the compound **4** against HIV-1 strains.

^c Compound **4** was tested in triplicate and the data presented as mean ± SD.

Table 6Inhibitory activity of **4** against HIV-1 RT resistant strains in MT-2 cell line

Multi-RT resistant HIV-1 strains	EC ₅₀ (μM)	
	4	Nevirapine
8605MR	1.81 (8.96-fold) *	>14.80 (>51.21-fold) *
6005MR	0.43 (2.13-fold) *	>14.80 (>51.21-fold) *
7324-1	3.93 (14.41-fold) *	>14.80 (>51.21-fold) *
Wild type -HIV-1_{IIIb}	0.20	0.29

8605MR: 41L, 67N, 210W, 215Y, 184V, 103N

6005MR: 41L, 74V, 184V, 210W, 215Y, ins SS, 98G

7324-1: multidrug resistant HIV-1 reverse transcriptase (RT) clone.

* Compared with EC₅₀ of wild-type virus

Table 7Antiviral activity of **4** against infection of PBMCs by primary HIV-1 isolates of distinct subtypes and tropisms

Isolates	Subtype	Tropism	EC ₅₀ (μM) [*]	EC ₉₀ (μM)
94UG103	A	X4R5	0.84 ± 0.07	1.63 ± 0.30
92US657	B	R5	5.09 ± 0.58	9.22 ± 1.02
93MW959	C	R5	0.87 ± 0.079	3.06 ± 0.68
92UG001	D	X4R5	0.98 ± 0.35	5.23 ± 2.44
93BR020	F	X4R5	2.18 ± 0.04	3.76 ± 0.13
RU570	G	R5	3.27 ± 0.17	8.93 ± 0.19
BCF02	Group O	R5	9.92 ± 1.15	18.1 ± 2.3

^{*} Tests were done in triplicate and the data presented as mean ± SD. The CC₅₀ value of **4** to PBMCs is >150 μM.

Table 8

Pharmacokinetic parameters of **4** in male Sprague-Dawley rats (180–200 g) by i.v. (2 mg/kg) and i.g. (20 mg/kg) dosing in 10% PEG400^a

Cmpd	Administration	CL (L/min/kg)	Vd (L/kg)	AUC(0-t) µg/L*min	t _{1/2} (min)	F(%)
4	i.v.	0.01±0.003	2.34±0.31	195270.08	97±11	
	i.g.	0.058±0.01	8.19±2.60	348067.29	167±30	17.8

^aCompound **4** was tested in triplicate and data presented as mean ± S (n = 3)